142 related articles for article (PubMed ID: 37962072)
1. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Rajdev L; Jackie Wang CC; Joshi H; Lensing S; Lee J; Ramos JC; Baiocchi R; Ratner L; Rubinstein PG; Ambinder R; Henry D; Streicher H; Little RF; Chiao E; Dittmer DP; Einstein MH; Cesarman E; Mitsuyasu R; Sparano JA;
Cancer; 2024 Mar; 130(6):985-994. PubMed ID: 37962072
[TBL] [Abstract][Full Text] [Related]
2. CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies.
Caby F; Guiguet M; Weiss L; Winston A; Miro JM; Konopnicki D; Le Moing V; Bonnet F; Reiss P; Mussini C; Poizot-Martin I; Taylor N; Skoutelis A; Meyer L; Goujard C; Bartmeyer B; Boesecke C; Antinori A; Quiros-Roldan E; Wittkop L; Frederiksen C; Castagna A; Thurnheer MC; Svedhem V; Jose S; Costagliola D; Mary-Krause M; Grabar S;
Clin Infect Dis; 2021 Jul; 73(1):50-59. PubMed ID: 34370842
[TBL] [Abstract][Full Text] [Related]
3. Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
Lavole A; Mazieres J; Schneider S; Brosseau S; Kiakouama L; Greillier L; Guihot A; Abbar B; Baron M; Makinson A; Langlais A; Morin F; Spano JP; Cadranel J;
Lung Cancer; 2021 Aug; 158():146-150. PubMed ID: 34217967
[TBL] [Abstract][Full Text] [Related]
4. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.
Galanina N; Goodman AM; Cohen PR; Frampton GM; Kurzrock R
Cancer Immunol Res; 2018 Oct; 6(10):1129-1135. PubMed ID: 30194084
[TBL] [Abstract][Full Text] [Related]
6. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.
Dubrow R; Qin L; Lin H; Hernández-Ramírez RU; Neugebauer RS; Leyden W; Althoff KN; Achenbach CJ; Hessol NA; Modur SP; DʼSouza G; Bosch RJ; Grover S; Horberg MA; Kitahata MM; Mayor AM; Novak RM; Rabkin CS; Sterling TR; Goedert JJ; Justice AC; Engels EA; Moore RD; Silverberg MJ;
J Acquir Immune Defic Syndr; 2017 Aug; 75(4):382-390. PubMed ID: 28394855
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
8. Kaposi sarcoma in people living with HIV: incidence and associated factors in a French cohort between 2010 and 2015.
Poizot-Martin I; Lions C; Cheret A; Rey D; Duvivier C; Jacomet C; Allavena C; Huleux T; Bani-Sadr F; Obry-Roguet V; Makinson A;
AIDS; 2020 Mar; 34(4):569-577. PubMed ID: 31764070
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir based therapy showed CD4
Gebremedhin T; Aynalem M; Adem M; Geremew D; Aleka Y; Kiflie A
Sci Rep; 2024 Feb; 14(1):3297. PubMed ID: 38331983
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
Uldrick TS; Gonçalves PH; Abdul-Hay M; Claeys AJ; Emu B; Ernstoff MS; Fling SP; Fong L; Kaiser JC; Lacroix AM; Lee SY; Lundgren LM; Lurain K; Parsons CH; Peeramsetti S; Ramaswami R; Sharon E; Sznol M; Wang CJ; Yarchoan R; Cheever MA;
JAMA Oncol; 2019 Sep; 5(9):1332-1339. PubMed ID: 31154457
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
14. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus.
Silverberg MJ; Leyden W; Hernández-Ramírez RU; Qin L; Lin H; Justice AC; Hessol NA; Achenbach CJ; D'Souza G; Engels EA; Althoff KN; Mayor AM; Sterling TR; Kitahata MM; Bosch RJ; Saag MS; Rabkin CS; Horberg MA; Gill MJ; Grover S; Mathews WC; Li J; Crane HM; Gange SJ; Lau B; Moore RD; Dubrow R; Neugebauer RS
Clin Infect Dis; 2021 Jun; 72(11):1900-1909. PubMed ID: 32785640
[TBL] [Abstract][Full Text] [Related]
15. Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study.
Rasmussen TA; Rajdev L; Rhodes A; Dantanarayana A; Tennakoon S; Chea S; Spelman T; Lensing S; Rutishauser R; Bakkour S; Busch M; Siliciano JD; Siliciano RF; Einstein MH; Dittmer DP; Chiao E; Deeks SG; Durand C; Lewin SR
Clin Infect Dis; 2021 Oct; 73(7):e1973-e1981. PubMed ID: 33677480
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.
Krown SE; Roy D; Lee JY; Dezube BJ; Reid EG; Venkataramanan R; Han K; Cesarman E; Dittmer DP
J Acquir Immune Defic Syndr; 2012 Apr; 59(5):447-54. PubMed ID: 22067664
[TBL] [Abstract][Full Text] [Related]
17. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study.
Maskew M; Fox MP; van Cutsem G; Chu K; Macphail P; Boulle A; Egger M; Africa FI
PLoS One; 2013; 8(6):e64392. PubMed ID: 23755122
[TBL] [Abstract][Full Text] [Related]
18. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
Li T; Dai Y; Kuang J; Jiang J; Han Y; Qiu Z; Xie J; Zuo L; Li Y
PLoS One; 2008; 3(12):e3918. PubMed ID: 19081791
[TBL] [Abstract][Full Text] [Related]
19. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for Kaposi's sarcoma in human immunodeficiency virus patients after initiation of antiretroviral therapy: A nested case-control study in Kenya.
Lupia R; Wabuyia PB; Otiato P; Fang CT; Tsai FJ
J Microbiol Immunol Infect; 2017 Dec; 50(6):781-788. PubMed ID: 26712092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
